Domingo J L, Gomez M, Sanchez D J, Llobet J M, Keen C L
Laboratory of Toxicology and Biochemistry, School of Medicine, University of Barcelona, Reus, Spain.
Life Sci. 1992;50(18):1311-7. doi: 10.1016/0024-3205(92)90281-s.
Although it has been reported that vanadate is effective in diminishing the expression of diabetes in the rat, the severe toxic side effects noted in the vanadate-treated animals suggest that chronic oral administration of vanadate argues against its use in human diabetes. The present study was conducted to evaluate the effects of the chelator Tiron on the mobilization of vanadium after administration of sodium metavanadate in the drinking water (0.20 mg/ml) of streptozotocin-induced diabetic rats for 35 days. Intraperitoneal treatment with Tiron (300 or 600 mg/kg) was initiated after three weeks of vanadate administration and continued for two weeks. The ameliorative effects of vanadium with respect to diabetes were not diminished by the administration of Tiron, but the accumulation of vanadium in kidney and bone was significantly decreased in the Tiron-treated groups and diabetes associated increases in serum GOT, GPT and cholesterol were diminished with Tiron treatment. It is concluded that the coadministration of metavanadate and Tiron may be of potential value for treatment of diabetes mellitus.
尽管有报道称钒酸盐可有效降低大鼠糖尿病的表现，但在接受钒酸盐治疗的动物中观察到的严重毒副作用表明，长期口服钒酸盐不利于其在人类糖尿病治疗中的应用。本研究旨在评估螯合剂钛铁试剂（Tiron）对链脲佐菌素诱导的糖尿病大鼠饮用含偏钒酸钠（0.20 mg/ml）的水35天后钒动员的影响。在给予钒酸盐三周后开始腹腔注射钛铁试剂（300或600 mg/kg），并持续两周。给予钛铁试剂并未降低钒对糖尿病的改善作用，但在接受钛铁试剂治疗的组中，肾脏和骨骼中钒的蓄积显著减少，且钛铁试剂治疗减轻了糖尿病相关的血清谷草转氨酶（GOT）、谷丙转氨酶（GPT）和胆固醇升高。结论是，偏钒酸盐与钛铁试剂联合给药可能对糖尿病治疗具有潜在价值。
